Managing Chemotherapy Related Toxicities in Metastatic Pancreatic Ductal Adenocarcinoma

This segment focuses on the management of two of the most common and disruptive toxicities in metastatic pancreatic ductal adenocarcinoma, diarrhea and pancreatic exocrine insufficiency. Faculty discuss how these complications affect treatment adherence, dose intensity, and quality of life for patients receiving combination chemotherapy.

Panelists explain how they distinguish chemotherapy related diarrhea from symptoms driven by pancreatic exocrine insufficiency, emphasizing the importance of accurate assessment to guide appropriate intervention. The discussion includes practical considerations for initiating pancreatic enzyme replacement therapy and nutritional supplementation.

Faculty highlight how early recognition and proactive supportive care can prevent unnecessary dose reductions or treatment discontinuation. By addressing these toxicities effectively, clinicians can help patients remain on therapy longer while preserving functional status and well being.

This segment provides actionable guidance for managing common treatment related challenges and reinforces the role of supportive care in optimizing outcomes for patients with metastatic pancreatic ductal adenocarcinoma.